Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Medicenna Therapeutics Corp ( (TSE:MDNA) ).
Medicenna Therapeutics has reshaped its board of directors by appointing Richard Sutin and Angelos Georgakis, effective February 12, 2026, while longtime director Karen Dawes retires from the board and transitions to a consulting role. The company expects Sutin’s capital markets and M&A expertise and Georgakis’ track record advising biotech leaders through financing, IPOs and strategic transactions to support its growth strategy and strengthen governance as it advances its immunotherapy pipeline.
The new directors bring deep experience in corporate law, capital markets and biotech leadership, with Sutin serving as a veteran corporate lawyer and board advisor, and Georgakis known for guiding life sciences companies through key inflection points. Their appointments underscore Medicenna’s focus on capital markets readiness and strategic execution, positioning the company to better navigate future funding, partnership or transaction opportunities in the competitive immunotherapy space.
The most recent analyst rating on (TSE:MDNA) stock is a Sell with a C$0.75 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Spark’s Take on TSE:MDNA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, ongoing losses, and significant cash burn) and bearish technicals (below major moving averages with negative momentum). Positive clinical and development-related corporate updates provide some offset, but valuation support is limited given negative earnings and no dividend.
To see Spark’s full report on TSE:MDNA stock, click here.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company developing novel Superkines, including highly selective IL-2, IL-4 and IL-13-based therapeutics, as well as first-in-class Empowered Superkines. Its pipeline features MDNA11, a next-generation IL-2 Superkine, MDNA113, a targeted PD-1 x IL-2 bispecific for solid tumors, and bizaxofusp for recurrent glioblastoma, which has received FastTrack and Orphan Drug designations.
Average Trading Volume: 137,383
Technical Sentiment Signal: Sell
Current Market Cap: C$52.23M
See more insights into MDNA stock on TipRanks’ Stock Analysis page.